Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Neoplasms 9Carcinoma, Hepatocellular 5Squamous Cell Carcinoma of Head and Neck 4Melanoma 3Colorectal Neoplasms 3Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Head and Neck Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Sarcopenia 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Myositis 1Metastatic Colorectal Adenocarcinoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Liver Neoplasms 1Hyperthermia 1Histiocytoma, Malignant Fibrous 1Hematologic Neoplasms 1Heart Diseases 1Glioma 1Eye Diseases 1Esophageal Squamous Cell Carcinoma 1

Interventions

pembrolizumab 3Ipilimumab 2Blood Specimen Collection 2spartalizumab 1necitumumab 1mirdametinib 1leronlimab 1apatinib 1Watchful Waiting 1Tomography, X-Ray Computed 1Therapeutics 1Surveys and Questionnaires 1Rosuvastatin Calcium 1Radiotherapy 1Radiation 1Positron-Emission Tomography 1PankoMab-GEX 1Panitumumab 1Nivolumab 1Metformin 1Magnetic Resonance Imaging 1MEK inhibitor I 1Jupiter 1JPT1 protein, human 1Interleukin-2 1Immune Checkpoint Inhibitors 1GAT 1Fluorodeoxyglucose F18 1FCN-437c 1EBI-005 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Tumor, Adult × Immune Checkpoint Inhibitors × Clear all
NCT04020185 2024-12-11

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

ImmuneSensor Therapeutics Inc.

Phase 1/2 Completed
40 enrolled 16 charts
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡